Advanced Practice

CAR T-cell therapy for children: Meeting patient and family needs

HemOnc Today, January 25, 2020
Amy Barry, MSN, RN, PPCNP-BC; Colleen Callahan, MSN, RN, CRNP; Diane Baniewicz, MSN, RN, CRNP
Chimeric antigen receptor T-cell therapy is a promising immunotherapy for children with refractory or relapsed acute lymphoblastic leukemia who…

Drug Pipeline

FDA clears IND application for natural killer cell therapy for glioblastoma multiforme

January 22, 2020
The FDA cleared an investigational new drug application for CYNK-001, a natural killer cell therapy, for the treatment of glioblastoma multiforme. …

Trend Watch

Astellas partners with Adaptimmune to develop off-the-shelf CAR-T and T-cell therapies

January 20, 2020
Astellas Pharma announced a research and commercialization deal with Adaptimmune for the codevelopment of new stem cell-derived allogeneic chimeric…

Physicians join John Theurer Cancer Center medical staff

January 18, 2020
John Theurer Cancer Center at Hacksensack University Cancer Center announced the appointment of five physicians to its medical staff.

Trend Watch

Cytovia partners with UCSF, New York Stem Cell Foundation to develop novel CAR-NK cell therapies

January 17, 2020
Cytovia Therapeutics announced research partnerships with both The New York Stem Cell Foundation Research Institute and University of California, San…

FDA News

Guide catheter for cardiac cell therapy delivery cleared

January 15, 2020
BioCardia announced that the FDA granted clearance to its deflectable guide catheter for delivery of cell therapy to the heart. The catheter (Morph…


‘Immunotransplant’ shows potential for non-Hodgkin lymphoma

January 13, 2020
A combination of immunotherapy and stem cell transplantation could benefit patients with treatment-resistant non-Hodgkin lymphoma, according to…

FDA News

FDA grants rare pediatric disease designation to gene therapy for sickle cell disease

January 10, 2020
The FDA granted rare pediatric disease designation to ARU-1801, an investigational autologous gene therapy, for the treatment of sickle cell disease…

Stem cell therapy for ACLF progresses to safety, efficacy trial

January 8, 2020
Promethera Biosciences announced the initiation of a phase 2b clinical trial to evaluate the safety and efficacy of HepaStem, a liver-derived stem…

FDA News

FDA grants orphan drug designation to PRGN-3006 for AML

January 6, 2020
The FDA granted orphan drug designation to PRGN-3006 for the treatment of relapsed or refractory acute myeloid leukemia, according to the…


An emerging industry looks to take T cells to the cryobank

December 30, 2019
An increasing body of evidence shows that using younger, less heavily pretreated T cells results in more effective chimeric antigen receptor T-cell…

Meeting NewsPerspective

Dual target CAR T/natural killer cell therapy shows promise for B-cell malignancies

December 27, 2019
ORLANDO — Two major impediments to widespread adoption of chimeric antigen receptor T-cell therapies are their cost and antigen loss that makes…

Meeting News

New gene therapy appears safe, feasible for sickle cell disease

December 26, 2019
ORLANDO — Significant induction of fetal hemoglobin after the infusion of CD34-positive cells occurred among a small cohort of patients with…

Meeting NewsPerspective

Mosunetuzumab induces remissions in advanced non-Hodgkin lymphoma after CAR-T fails

December 23, 2019
ORLANDO — About 20% of a cohort of patients with aggressive relapsed or refractory non-Hodgkin lymphoma experienced complete response to…

Drug Pipeline

Bristol-Myers Squibb seeks FDA biologics license for CAR T-cell therapy in advanced large B-cell lymphoma

December 19, 2019
Bristol-Myers Squibb has submitted a biologics license application to the FDA for the company’s investigational chimeric antigen receptor…

Patient-derived stem cell therapy trial for geographic atrophy launches

December 17, 2019
A clinical trial testing the safety of a patient-specific stem cell-based therapy for the treatment of geographic atrophy has been launched by the…

Drug Pipeline

Kite submits BLA to FDA for CAR T-cell therapy in mantle cell lymphoma

December 12, 2019
Biopharma company Kite, a subsidiary of Gilead, has submitted a biologics license application to the FDA for the company’s investigational…

Meeting NewsVideo

Early steroid use may reduce CAR T-cell treatment-related toxicity in aggressive lymphoma

December 12, 2019
ORLANDO — Early steroid use appeared to reduce the incidence of severe cytokine release syndrome and neurotoxicity without affecting response…

Meeting NewsPerspective

BCMA-directed CAR-T induces early, deep responses in advanced multiple myeloma

December 8, 2019
ORLANDO — An investigational chimeric antigen receptor T-cell therapy that targets the B-cell maturation antigen induced response in 100% of…

Meeting NewsPerspective

CAR T-cell therapy offers benefit, reduces health care utilization for older patients with DLBCL

December 8, 2019
ORLANDO — Older patients with multiple comorbidities can successfully undergo chimeric antigen receptor T-cell therapy for non-Hodgkin…